Interferon beta-1a
- Generic Name
- Interferon beta-1a
- Brand Names
- Avonex, Rebif
- Drug Type
- Biotech
- CAS Number
- 145258-61-3
- Unique Ingredient Identifier
- XRO4566Q4R
- Background
Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta.
- Indication
For treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2008-01-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 14
- Registration Number
- NCT00492466
- Locations
- 🇫🇮
Coordinating Research Site, Turku, Finland
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 380
- Registration Number
- NCT00492765
- Locations
- 🇩🇰
Coordinating Research Site, Copenhagen, Denmark
Rebif New Formulation (RNF) Quality of Life (QOL) Study
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 232
- Registration Number
- NCT00472797
- Locations
- 🇺🇸
EMD Serono, Inc., Rockland, Massachusetts, United States
Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 150
- Registration Number
- NCT00463710
- Locations
- 🇺🇸
The Jacobs Neurological Institute, Buffalo, New York, United States
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 180
- Registration Number
- NCT00441103
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Drug: Betaferon/Betaseron
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2013-10-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 220
- Registration Number
- NCT00317941
Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease
- Conditions
- Crohn's Disease
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2013-08-06
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 192
- Registration Number
- NCT00304252
- Locations
- 🇬🇧
Medical Information Office, Feltham, United Kingdom
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2013-08-05
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 677
- Registration Number
- NCT00292266
A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 35
- Registration Number
- NCT00287079
- Locations
- 🇨🇦
Canadian Medical Information Office, Windsor, Barrie, Hamilton, Mississauga, Ontario, Canada
A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2013-08-06
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 257
- Registration Number
- NCT00249860
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.